Clinical trials: Platelet Derived Growth Factor
Colorectal Neoplasm, Colorectal Cancer
New Individualized Therapy Trial for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of imatinib mesylate in combination with panitumumab for the treatment of stage IV colorectal cancer that has spread to the liver.
- Trial name
- NITMEC (NCT00867334)
- Testing
- Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inova Health Care Services
Osteo Arthritis Knee
Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis
the study was conducted on 31-patients with symptomatic primary knee osteoarthritis. The patients were randomized into intervention and control groups. The control group was kept on their medications without intervention.
- Trial name
- NCT04331327
- Testing
- allogenic lyophilized growth factors
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Rasmia Elgohary
Knee Osteoarthrosis
Treatment of Knee Arthrosis With Platelet-derived Growth Factors vs. Hyaluronic Acid.
Primary aim of this trial was to assess efficacy three intraarticular injections of platelet lysate when compared to hyaluronic acid.
- Trial name
- NCT02958761
- Testing
- intraarticular injections of platelet lysate, hyaluronic acid
- Volunteers
- 58 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Platelet-Derived Growth Factor, Diabetic Foot
Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers
The purpose of this study is to retrospectively evaluate the safety of sterile becaplermin gel compared with sterile placebo gel treatment 12 months or more after the last dose was administered in 1 of 2 double-blind trials…
- Conditions
- Platelet-Derived Growth Factor, Diabetic Foot, Neoplasms
- Trial name
- NCT00740922
- Volunteers
- 563 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Advanced Cancer
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules called "angiogenic factors" that may cause tumors to grow.
- Trial name
- NCT02747797
- Testing
- Lucitanib
- Where
- United States
- Sponsor
- Teresa Helsten, MD
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Non-small Cell Lung Cancer
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer…
- Trial name
- NCT01268059
- Testing
- Carboplatin, Paclitaxel, MEDI-575
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 99 people
- Sponsor
- MedImmune LLC
Cancer
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
- Trial name
- MEDI-575 (NCT00816400)
- Testing
- MEDI-575
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Solid Tumors
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
- Trial name
- NCT00768391
- Testing
- IMC-3G3
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Glioma, High Grade Glioma
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)…
- Conditions
- Glioma, High Grade Glioma, Pontine Tumors
- Trial name
- NCT03352427
- Testing
- Dasatinib, Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Diabetes Mellitus
The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])
The purpose of this study is to compare the risk of cancers in patients who have used REGRANEX (becaplermin) to that of patients with similar characteristics and health issues who have not used REGRANEX (becaplermin).
- Trial name
- NCT00518102
- Testing
- REGRANEX (becaplermin), REGRANEX (becaplermin) comparators
- Volunteers
- 4,431 people
- Sponsor
- Ethicon, Inc.
Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), can improve the disease condition in patients with hypereosinophilic syndrome, polycythemia vera, atypical CML or CMML with…
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome
- Trial name
- NCT00038675
- Testing
- Imatinib Mesylate (Gleevec)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor, PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant to imatinib mesylate (Gleevec).
- Trial name
- NCT00117299
- Testing
- PTK787/ZK222584
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- University of Helsinki
Gingival Overgrowth
Assessment of Growth Factors Levels Associated with Wound Healing After Soft Tissue Crown Lengthening
Clinicians often encounter the need for crown lengthening in the practice of dentistry and have to make treatment decisions taking into consideration how to best address the biological, functional, and esthetic requirements of…
- Trial name
- NCT06806319
- Testing
- single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm, single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Al-Azhar University
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Wounds and Injuries, Diabetes
Gene Therapy to Improve Wound Healing in Patients With Diabetes
Patients with diabetes may develop chronic wounds that respond poorly to treatment. Gene therapy with the platelet-derived growth factor-B gene has been shown to help with the healing of chronic wounds.
- Conditions
- Wounds and Injuries, Diabetes, Diabetic Foot Ulcers, Foot Wounds
- Trial name
- NCT00065663
- Testing
- GAM501
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tissue Repair Company
Chordoma
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma.
- Trial name
- NCT01175109
- Testing
- Imatinib + LBH589
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Deric M Park MD